\
&
Contact us
\
&
Contact us
Published on | 2 years ago
Programmes Digital, Industry & SpaceFollowing the successful previous Full Proposal Checks events (FPC), Ideal-ist, the international network of ICT national contact points, is organizing a Full Proposal Check Event for the first Horizon Europe Cluster 4 Digital call topics in 2023.
When
The events will be held online between the 27th of February and the 2nd of March 2023.
Where
All information can be found at https://idealist.proposalcheck.eu/. All interaction with the proposers will also be made via the website.
Procedure
The deadline for the targeted call topics is the 29 th of March 2023. Interested proposers must:
1. Register their Expression of Interest (EoI) as soon as possible before the 10th of February 2023, and
2. Provide an advanced-almost complete draft of their proposal before the 17th of February 2023.
We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).
Stay informed about what matters to you.
By signing up, you can opt in for e-mail notifications and get access to
a personalised dashboard that groups all news updates and event announcements in your domain(s).
Only for stakeholders located in Flanders
The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.
